Effect Of Haridra Churna (Haldi) in Reducing Blood Sugar in Madhumeha (Diabetes Mellitus)
- Conditions
- Type 2 diabetes mellitus without complications,
- Registration Number
- CTRI/2020/02/023430
- Lead Sponsor
- Department of Kayachikitsa Ch Brahm Prakash Ayurved Charak Sansthan
- Brief Summary
*Madhumeha* isa clinical entity described in Ayurveda as one of the types of*Vataja* *Prameha*.Regarding this disease Ayurvedic scholars have mentioned that *Madhumeh*ais caused by aggravation of *Vata*, the patient passes excess urinewhich is sweet, astringent in taste, slightly turbid and pale incolor. Describing the *Prameha*, the cardinal feature of *Prameha* hasbeen mentioned as *Avile Prabhuta Mutrata.* *Madhumeha* iscaused by*Dhatukshaya* manifests as thin and asthenicindividual due to loss of *Oja* or imbalance in *Oja.* In *MargavaranjanyaMadhumeha* the vitiated *Kapha*and *Meda* obstructthe passage of Vata. The obstructed *Vata*is vitiated again andcarries *Ojas* to*Basti* thus manifests *Madhumeha.*
*Madhumeha* can be correlated with a similar disease described in modernmedical sciences as Diabetes mellitus, which is a syndrome with disorderedmetabolism and inappropriate hyperglycemia, due to either a deficiency ofinsulin secretion or to a combination of insulin resistance and inadequateinsulin secretion to compensate. Diagnostic emphasis then shifted to theglucose levels themselves and in addition to diabetes a milder level ofhyperglycemia denoted impair glucose tolerance has been defined by the W.H.O.
Aim is to compare the Hypoglycaemic effect of *HaridraChurna and Chandraprabha Vati*in *Madhumeha*(Type 2Diabetes Mellitus) along with *Pippali Churna* asadjuvant. Objectives are to evaluate the effectiveness of *HaridraChurna*along with *Pippali Churna* as adjuvantin *Madhumeha*(Type2 Diabetes Mellitus), To evaluate the effectiveness of *ChandraprabhaVati*along with *Pippali Churna* asadjuvant in *Madhumeha*(Type 2 DiabetesMellitus), To compare the hypoglycemic effect of *HaridraChurna and Chandraprabha Vati*in *Madhumeha*(Type 2Diabetes Mellitus) along with *Pippali Churna* as adjuvant.
Study design is Single centred, Open label, ComparativeStudy, Randomized control study, Efficacy study, with one of active controlwithout any crossover. Study area is OPD & IPD of Ch. BrahmPrakash Ayurveda Charak Sansthan, Khera Dabar, New Delhi. Study populationis Diagnosed patients of Type-2 Diabetes Mellitus will be selected forthis purpose on the basis of inclusion criteria. Detail of drugadministration is *Haridra Churna*– In dosage of 3gm twice in aday for 21 days with ‘*Pippali Churna*’ 500mg half an hour before mealin Group A (Trial group). *Chandraprabha Vati*– in dosage of 500mg twice in a day for 21 days with ‘*Pippali Churna*’ 500mg half an hourbefore meal in Group B (Comparator group).
Inclusion criteria involves 1. Patientswith age between 40-60yrs. 2. Sex: Both male and female.3. Patients fulfilling the diagnostic criteria for Diabetes Mellitusframed by the AMERICAN DIABETES ASSOCIATION. 3. FBS-126-200mg/dlPPBS-150-350 mg/dl. 4. HbA1c 7% and more. Patients taking any type oforal anti-diabetic treatment from 1. Biguanides and 2. Sulfonylurea. Exclusioncriteria involves 1. Patients below the age of 40 years and morethan the age of 60 years, 2. FastingBlood Sugar Level <126 mg/dl and >200 mg/dPost Prandial Blood Sugar Level<180 mg/dl and >350 mg/dl 3. HbA1c<7%, 4. Patients depending on the insulin for blood glucosecontrol, 5. Patients with diabeticcomplications, 6. Patients suffering from Secondary Diabetes, 7. Gestationaldiabetes, 8. Pregnant ladies andlactating mothers. Assesment criteria involves SUBJECTIVE criteriasare 1. *Prabhootmutrata, 2. Avilamutrata, 3. MutraMadhuryata, 4. Swapnasheela, Aasansheela, Atikshudha, Atisweda, Daurbalya,Atitrushna.*Objective criteria involves 1. FBS AND PPBS, 2.Urine (Routine and Microscopic)
Patients will be clinically assessed on day 0,1,7,14,21 days forefficacy and findings would be noted in specified proforma and follow up of thesubjects will be done after 21 days the *Haridra Churna* with ‘*PippaliChurna*’ has been administered. The response of the patient’s diseasedcondition will be observed and recorded before, during and after the treatmentin a specially designed case proforma includes detailed history, physicalexamination, laboratory investigations and assessment based on subjective andobjective parameters for which appropriate scoring pattern is adopted.Totalduration of study is 42 Days. Duration of Haridra churnaadministration is 21 day. Follow up will be done on 42ndday
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 40
- Patients with age between 40-60yrs.
- Sex: Both male and female 3.
- Patients fulfilling the diagnostic criteria for Diabetes Mellitus framed by the AMERICAN DIABETES ASSOCIATION.
- FBS-126-200mg/dl PPBS-150-350mg/dl 5.HbA1c 7% and more 6.Patients taking any type of oral anti-diabetic treatment from 1.
- Biguanides and 2.
- Sulfonylurea 1.
- FBS-126-200mg/dl PPBS-150-350mg/dl 5.
- HbA1c 7% and more 6.
- Patients taking any type of oral anti-diabetic treatment from 1.
- Sulfonylurea.
- Patients below the age of 40 years and more than the age of 60 years 2.
- Fasting Blood Sugar Level <126 mg/dl and >200 mg/dl • Post Prandial Blood Sugar Level <180 mg/dl and >350 mg/dl 3.
- Patients depending on the insulin for blood glucose control.
- Patients with diabetic complications.
- Patients suffering from Secondary Diabetes.
- Gestational diabetes.
- Pregnant ladies and lactating mothers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in Prabhootmutrata (excessive urine) Prabhootmutrata (excessive urine) | Avilamutrata (Turbid urine) | Mutra Madhuryata (Sweetness in urin) | Swapnasheela (sleep) | Atikshudha | (Excessive hunger) | Atisweda (Excessive sweating) | Daurbalya (Weakness) | Atitrushna (Excessive thirst) | on Day 0 Day1 Day 7 Day 14 Day 21 Reduction in Avilamutrata (Turbid urine) Prabhootmutrata (excessive urine) | Avilamutrata (Turbid urine) | Mutra Madhuryata (Sweetness in urin) | Swapnasheela (sleep) | Atikshudha | (Excessive hunger) | Atisweda (Excessive sweating) | Daurbalya (Weakness) | Atitrushna (Excessive thirst) | on Day 0 Day1 Day 7 Day 14 Day 21 Reduction in Mutra Madhuryata (Sweetness in urine) Prabhootmutrata (excessive urine) | Avilamutrata (Turbid urine) | Mutra Madhuryata (Sweetness in urin) | Swapnasheela (sleep) | Atikshudha | (Excessive hunger) | Atisweda (Excessive sweating) | Daurbalya (Weakness) | Atitrushna (Excessive thirst) | on Day 0 Day1 Day 7 Day 14 Day 21
- Secondary Outcome Measures
Name Time Method Reduction in swapnasheela (sleep) Reduction in atikshudha
Trial Locations
- Locations (1)
Chaudhary Brahm Prakash Ayurved Charak Sansthan Khera Dabar New Delhi
🇮🇳West, DELHI, India
Chaudhary Brahm Prakash Ayurved Charak Sansthan Khera Dabar New Delhi🇮🇳West, DELHI, IndiaProf Dr N R SinghPrincipal investigator9560659728naimishraj@yahoo.com